BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) — Duck Creek Technologies, the global intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, announced it received for a third consecutive year the prestigious 2025 5-Star Diversity, Equity, and Inclusion Award by Insurance Business America. This recognition underscores Duck Creek's steadfast commitment to […]

(NasdaqGM:ACTU), CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3B), today announced that Daniel Schmitt, President & Chief Executive Officer

(NASDAQ:NVEE), HOLLYWOOD, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), NV5, a provider of technology, certification, and consulting solutions, announced today that it has been awarded $5 million in substation design contracts by Northeast utilities. These projects will strengthen electrical grid reliability and support the resiliency of

Boston, MA, Feb. 06, 2025 (GLOBE NEWSWIRE) — Today, the Kraft Center for Community Health at Mass General Brigham announced the launch of the inaugural Kraft Prize for Excellence and Innovation in Community Health. This national prize seeks to honor a transformative organization, program or innovation that is making a measurable impact on health outcomes

(NASDAQ:TNXP), Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 30 mg/kg i.v. doses TNX-1500 showed mean half-life of 34-38 days for the

(NASDAQ:ALHC), ORANGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2024 financial results on Thursday, Feb. 27, 2025, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EST. Conference Call DetailsA live

(NASDAQ:GLTO), BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) — EnsembleIQ's Product of the Year Canada, the largest consumer-voted, globally recognized award for product innovation, today announces the winners of the 2025 Product of the Year Awards. With winners across 43 distinct categories, the products are awarded Product of the Year for outstanding innovation through a national survey

(NASDAQ:PCRX), PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 4, 2025 to 15 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the

(NASDAQ:KRYS), PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call